Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current.

Displaying 1 - 34 of 34

	Date Sort ascending
CL_2024-34.pdf	2024-11-20	INFORMATION ONLY Leukoreduced Whole Blood Clinical Studies: Second Update Customer Letter 2024-34 (PDF) \| Canadian Blood Services Leukoreduced Whole Blood Program for Non-Military Use (PDF)
CL_2024-33.pdf	2024-10-18	INFORMATION ONLY SD Plasma Expiry Date Discrepancy Customer Letter 2024-33 (PDF) \| Octaplasma Difference in Date Formatting (PDF)
CL_2024-32.pdf	2024-09-20	INFORMATION ONLY Introduction of CBS Manufactured Pathogen Reduced Plasma (Apheresis Multiplasma) Customer Letter 2024-32 (PDF)
CL_2024-31.pdf	2024-09-12	INFORMATION ONLY New PPRP Content Sheet for Shipping Box Customer Letter 2024-31 (PDF)
CL_2024-30.pdf	2024-09-12	INFORMATION ONLY Leukoreduced Whole Blood Clinical Studies Customer Letter 2024-30 (PDF)
CL_2024-29.pdf	2024-09-03	INFORMATION ONLY Replacement of Plasma Protein and Related Products (PPRP) Customer Table of Information with E-Formulary Customer Letter 2024-29 (PDF)
CL_2024-28.pdf	2024-07-31	INFORMATION ONLY Bayer Introduction of 2-Dimensional Barcodes Customer Letter 2024-28 (PDF) \| Bayer Letter (PDF)
CL_2024-27.pdf	2024-06-11	INFORMATION ONLY Gammagard SD Label and Diluent Update Customer Letter 2024-27 (PDF) \| Takeda Letter (PDF)
CL_2024-26.pdf	2024-06-05	INFORMATION ONLY Updated Glassia Implementation FAQ (version 2) Customer Letter 2024-26 (PDF) \| Glassia Implementation FAQ Version 2 (PDF)
CL_2024-25.pdf	2024-05-31	INFORMATION ONLY Form Change – Manitoba Hospital Customers Only – Platelet Immunology Laboratory, HLA Disease Association Customer Letter 2024-25 (PDF)
CL_2024-24.pdf	2024-05-31	INFORMATION ONLY Formulary Delisting of WinRho 5000 IU Customer Letter 2024-24 (PDF)
CL_2024-23.pdf	2024-05-13	INFORMATION ONLY SD Plasma Expiry Dates Customer Letter 2024-23 (PDF) \| Plasma Expiry Date Examples (PDF) \| Variable Data (PDF)
CL_2024-22.pdf	2024-05-13	INFORMATION ONLY Updated Hospital Customer Order Forms – Special Request Order Form and Hospital Customer Order Form Customer Letter 2024-22 (PDF)
CL_2024-21.pdf	2024-05-06	INFORMATION ONLY Ondexxya (andexanet alfa) Listing Decision Customer Letter 2024-21 (PDF)
CL_2024-20.pdf	2024-05-03	INFORMATION ONLY WinRho Label Change Customer Letter 2024-20 (PDF) \| Change of Packaging WinRho^® 600 IU 120mcg (PDF)
CL_2024-19.pdf	2024-04-29	INFORMATION ONLY Manitoba Hospital Customers Only, Change of Testing Location for Disease Associated Markers Customer Letter 2024-19 (PDF)
CL_2024-18.pdf	2024-04-28	INFORMATION ONLY Testing Changes, Change of Testing Location Customer Letter 2024-18 (PDF)
CL_2024-17.pdf	2024-04-08	INFORMATION ONLY New Tamper Seals Customer Letter 2024-17 (PDF)
CL_2024-16.pdf	2024-03-22	INFORMATION ONLY Octaplasma Label Changes Customer Letter 2024-16 (PDF) \| Enhanced Octaplasma^® Labels for Canadian Customers (PDF)
CL_2024-15.pdf	2024-03-15	INFORMATION ONLY Takeda Product Updates Customer Letter 2024-15 (PDF) \| Takeda Letter (PDF)
CL_2024-14.pdf	2024-03-13	INFORMATION ONLY Release of Revised Circulars of Information for Pooled Platelets Psoralen Treated, Apheresis Platelets Psoralen Treated and Apheresis Platelets PAS Added Customer Letter 2024-14 (PDF)
CL_2024-13.pdf	2024-03-12	INFORMATION ONLY Further updates to Ig Transitions FAQ regarding the Request for Proposals (RFP) for Immunoglobulins and other Plasma Protein and Related Products (PPRP) Customer Letter 2024-13 (PDF) \| 2024 Ig Transition FAQ (PDF)
CL_2024-12.pdf	2024-03-11	INFORMATION ONLY Hizentra 20% 10g Pre-Filled Syringe Update Customer Letter 2024-12 (PDF) \| Hizentra^® 50mL Pre-filled Syringe (PDF) \| Hizentra^®Tool (PDF)
CL_2024-11.pdf	2024-02-28	INFORMATION ONLY Glassia Update Customer Letter 2024-11 (PDF) \| Glassia Implementation FAQ (PDF)
CL_2024-10.pdf	2024-02-20	ACTION REQUIRED National Deployment of Pathogen-Reduced Platelets: Sixth Update Customer Letter 2024-10 (PDF)
CL_2024-09.pdf	2024-02-13	INFORMATION ONLY Introducing Hizentra 20% 10g Pre-Filled Syringe Customer Letter 2024-09 (PDF)
CL_2024-08.pdf	2024-02-05	INFORMATION ONLY Temporary Changes to Gammagard S/D Customer Letter 2024-08 (PDF) \| GAMMAGARD^®Customer Letter (PDF)
CL_2024-07.pdf	2024-02-05	INFORMATION ONLY Updated FAQ for the Request for Proposals (RFP) for Immunoglobulins and other Plasma Protein and Related Products (PPRP) Customer Letter 2024-07 (PDF) \| 2024 Ig Transition FAQ (PDF)
CL_2024-06.pdf	2024-01-30	INFORMATION ONLY Updated NAC Recommendations for Use of Irradiated Blood Components in Canada Customer Letter 2024-06 (PDF)
CL_2024-05.pdf	2024-01-29	ACTION REQUIRED New Visual Inspection Tool (VIT) Customer Letter 2024-05 (PDF)
CL_2024-04.pdf	2024-01-22	INFORMATION ONLY Glassia Launch Update Customer Letter 2024-04 (PDF) \| Introducing GLASSIA^® in Canada (PDF)
CL_2024-03.pdf	2024-01-22	INFORMATION ONLY Introducing Rebinyn 3000IU and Esperoct 3000IU Customer Letter 2024-03 (PDF)
CL_2024-02.pdf	2024-01-22	INFORMATION ONLY Illegible Lots on CSL’s Alburex 25% 100mL Customer Letter 2024-02 (PDF) \| Variable Printed Information on Alburex-25 Cartons (PDF)
CL_2024-01.pdf	2024-01-15	INFORMATION ONLY Discontinuation of Directed Donations Customer Letter 2024-01 (PDF)